Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Gsk Plc ADR (GSK)

Gsk Plc ADR (GSK)
33.82 -0.66 (-1.91%) 14:01 ET [NYSE]
33.82 x 1,600 33.83 x 300
Realtime by (Cboe BZX)
33.82 x 1,600 33.83 x 300
Realtime 34.21 -0.27 (-0.78%) 09:30 ET
Quote Overview for Thu, Apr 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
32.73
Day High
34.26
Open 34.24
Previous Close 34.48 34.48
Volume 5,023,509 5,023,509
Avg Vol 5,490,519 5,490,519
Stochastic %K 17.09% 17.09%
Weighted Alpha -20.53 -20.53
5-Day Change -5.60 (-14.36%) -5.60 (-14.36%)
52-Week Range 31.72 - 45.92 31.72 - 45.92
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 71,366,360
  • Shares Outstanding, K 2,069,790
  • Annual Sales, $ 40,095 M
  • Annual Income, $ 3,291 M
  • EBIT $ 5,138 M
  • EBITDA $ 8,398 M
  • 60-Month Beta 0.56
  • Price/Sales 1.76
  • Price/Cash Flow 6.12
  • Price/Book 4.23

Options Overview Details

View History
  • Implied Volatility 39.05% ( -5.34%)
  • Historical Volatility 32.40%
  • IV Percentile 98%
  • IV Rank 75.19%
  • IV High 50.40% on 04/08/25
  • IV Low 4.64% on 08/29/24
  • Put/Call Vol Ratio 0.92
  • Today's Volume 1,639
  • Volume Avg (30-Day) 6,487
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 135,001
  • Open Int (30-Day) 124,491

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 1.06
  • Number of Estimates 5
  • High Estimate 1.17
  • Low Estimate 0.96
  • Prior Year 1.09
  • Growth Rate Est. (year over year) -2.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.38 +3.18%
on 04/09/25
Period Open: 40.32
40.47 -17.43%
on 03/17/25
-6.91 (-17.14%)
since 03/10/25
3-Month
31.72 +5.34%
on 01/14/25
Period Open: 33.09
40.81 -18.12%
on 03/10/25
+0.32 (+0.97%)
since 01/10/25
52-Week
31.72 +5.34%
on 01/14/25
Period Open: 40.69
45.92 -27.25%
on 05/15/24
-7.28 (-17.89%)
since 04/10/24

Most Recent Stories

More News
PFE Secures EU Nod for Expanded Use of RSV Vaccine Abrysvo

Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization to expand the use of its RSV vaccine, Abrysvo. The vaccine has been approved for the prevention of lower...

MRNA : 24.57 (-7.87%)
GSK : 33.82 (-1.91%)
PFE : 21.57 (-4.09%)
GILD Stock Down on Report of Cut in HIV Prevention Spending

Shares of Gilead Sciences, Inc. GILD were down 2.47% after the Wall Street Journal reported that The Health and Human Services Department is evaluating plans to slash the federal government funding for...

GILD : 101.84 (-3.24%)
GSK : 33.82 (-1.91%)
PFE : 21.57 (-4.09%)
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?

GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. The stock has...

NVO : 61.23 (-5.93%)
LLY : 718.95 (-4.61%)
HLN : 9.65 (-0.16%)
GSK : 33.82 (-1.91%)
Pfizer Sells Remaining 7.3% Stake in Haleon for Around 3.3B

Pfizer PFE has sold off its remaining stake in consumer health company Haleon HLN to institutional investors and Haleon itself for around $3.3 billion. Pfizer sold its 7.3% stake in Haleon, or approximately...

JNJ : 148.26 (-1.80%)
HLN : 9.65 (-0.16%)
GSK : 33.82 (-1.91%)
PFE : 21.57 (-4.09%)
INCY Stock Down on Disappointing Skin Disease Study Data

Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral small-molecule JAK1 inhibitor, povorcitinib, for the treatment of hidradenitis suppurativa...

BMRN : 56.67 (-4.64%)
INCY : 55.57 (-5.59%)
GILD : 101.84 (-3.24%)
GSK : 33.82 (-1.91%)
Moderna Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?

Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25.Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft sales performance...

MRK : 77.20 (-5.75%)
MRNA : 24.57 (-7.87%)
GSK : 33.82 (-1.91%)
PFE : 21.57 (-4.09%)
GILD Stock Trading Close to Its 52-Week High: Should You Buy or Sell?

Gilead Sciences, Inc. GILD hit a 52-week high of $119.96 on March 10. The stock is currently trading at $111.44.Shares have also gained 5.5% in the past month compared with the industry’s growth of 1.2%....

MRK : 77.20 (-5.75%)
GILD : 101.84 (-3.24%)
GSK : 33.82 (-1.91%)
GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive

Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir.Lenacapavir is a novel, once-yearly injectable HIV-1 capsid inhibitor, for the...

GILD : 101.84 (-3.24%)
GSK : 33.82 (-1.91%)
PFE : 21.57 (-4.09%)
World Cancer Day Sparks Big Questions About Pollution, Genetics, and Innovation

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As World Cancer Day (Feb. 4) fades into the rearview, attention is shifting to the latest discussions...

ONCY : 0.4990 (-3.98%)
ZNTL : 1.1250 (-3.85%)
NYT : 47.94 (-0.91%)
ABSI : 2.46 (-4.65%)
GOVX : 0.9800 (-5.77%)
ONC.TO : 0.70 (-5.41%)
GSK : 33.82 (-1.91%)
Should You Buy, Hold or Sell Moderna Stock Post Q4 Earnings Release?

Last Friday, Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined significantly when compared to the previous year.Adjusted loss was $2.50...

MRK : 77.20 (-5.75%)
MRNA : 24.57 (-7.87%)
GSK : 33.82 (-1.91%)
PFE : 21.57 (-4.09%)
InterCure Expects to Publish its full Audited Fourth Quarter and Full Year 2021 Results Prior to the TSX Closing on April 5, 2022

Delay in publication of the Audited Results due to immaterial technical audit matters The Company expects the Audited Results will not differ from...

INCR.TO : N/A (N/A)
INCR : 1.2200 (-3.17%)
INCR-U.TO : 1.53 (+4.08%)
CORRECTING and REPLACING -- InterCure Estimates Record Fourth Quarter and Fiscal Year End 2021 Results(1)

Fourth quarter 2021 Revenue and Adjusted EBITDA2 of $33 million and $9 million, representing an increase of almost 200% and 140% YoY, respectively Record...

INCR.TO : N/A (N/A)
INCR : 1.2200 (-3.17%)
INCR-U.TO : 1.53 (+4.08%)
InterCure Estimates Record Fourth Quarter and Fiscal Year End 2021 Results(1)

Fourth quarter 2021 Revenue and Adjusted EBITDA2 of $33 million and $9 million, representing an increase of almost 200% and 140% YoY, respectively Record...

INCR.TO : N/A (N/A)
INCR : 1.2200 (-3.17%)
INCR-U.TO : 1.53 (+4.08%)
InterCure to Announce Q4 & Year-End 2021 Financial Results on April 4, 2022

Will release financial results for the fourth quarter of 2021 before market open on Monday, April 4, 2022 Webcast scheduled for same day at 8:30am ET ...

INCR.TO : N/A (N/A)
INCR : 1.2200 (-3.17%)
INCR-U.TO : 1.53 (+4.08%)
InterCure and Clever Leaves Announce International Strategic Partnership

Leading Global Cannabis Companies InterCure and Clever Leaves partner together to cultivate, market and distribute Pharmaceutical-Grade Medical Cannabis in...

CLVR : 0.0002 (unch)
CLVRW : 0.0150 (-40.00%)
INCR-U.TO : 1.53 (+4.08%)
INCR : 1.2200 (-3.17%)
InterCure to Participate in ROTH Capital’s 34th Annual Conference

Mr. Rabinovitch is one of the global cannabis senior executives to participate...

INCR.TO : N/A (N/A)
INCR-U.TO : 1.53 (+4.08%)
INCR : 1.2200 (-3.17%)
InterCure Announces Partnership with Altman Health

The partnership will focus on the new CBD wellness market in Israel Israeli Minister of Health announced yesterday that CBD will be removed from...

INCR.TO : N/A (N/A)
INCR : 1.2200 (-3.17%)
INCR-U.TO : 1.53 (+4.08%)
InterCure Signs Definitive Agreement to Acquire Multi-National Medical Cannabis Producer “Better”

Marking the First Major Consolidation in Pharmaceutical Grade Medical Cannabis Market Acquisition is Expected to be Accretive Strengthen InterCure’s...

INCR.TO : N/A (N/A)
INCR : 1.2200 (-3.17%)
INCR-U.TO : 1.53 (+4.08%)
InterCure Reports Record Preliminary 2021 Fourth Quarter Revenue - 3 Times YoY and 24% QoQ Growth

Estimated revenue reaches over CAD$31 million (a record NIS 77 million) Anticipates continued increases in adjusted operating profit and EBITDA ...

INCR.TO : N/A (N/A)
INCR : 1.2200 (-3.17%)
INCR-U.TO : 1.53 (+4.08%)
InterCure Announces European Expansion with International Cannabis Brand Cookies

Leading Global Cannabis Company InterCure Partners with Cookies to Open Retail Locations in Austria and the U.K. in Early 2022...

INCR.TO : N/A (N/A)
INCR-U.TO : 1.53 (+4.08%)
INCR : 1.2200 (-3.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 37.89
2nd Resistance Point 36.37
1st Resistance Point 35.42
Last Price 33.82
1st Support Level 32.96
2nd Support Level 31.44
3rd Support Level 30.49

See More

52-Week High 45.92
Fibonacci 61.8% 40.50
Fibonacci 50% 38.82
Fibonacci 38.2% 37.14
Last Price 33.82
52-Week Low 31.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar